The Trust will achieve this mission by a strategy of focused growth in aspects of heart and lung treatment, such as congenital heart disease, arrhythmia, advanced lung diseases and heart failure. Our business model can be summarised as:
- Continual development of leadingedge services through clinical refinement and research
- Effective and efficient delivery of core specialist treatment
- Managing the transition of more routine services to other centres to release capacity for new interventions.
We will remain autonomous while embracing effective partnerships
Remaining an autonomous, specialist organisation is central to preserving and building on our strong clinical and organizational record.
However, we are equally convinced of the importance of effective partnerships, particularly with major academic bodies to ensure a continuing pipeline of innovations to develop future treatments.
